Virginia has put a legal mechanism in place to recognize a future federally approved psilocybin medicine, but the change does not legalize psychedelic mushrooms now and would not make treatment immediately available after a federal decision.
Senate Bill 379, effective July 1, directs the Virginia Board of Pharmacy to reschedule a psilocybin formulation only after two federal steps occur: the Food and Drug Administration must approve a formulation intended for administration by a health professional in a health-care setting, and federal regulators must publish a final or interim scheduling order. The board would then act at its next quarterly meeting after 30 days have passed from that publication.
The narrow language matters. The enacted Chapter 306 is a trigger for a specific medical product, not a general decriminalization measure and not permission for home-grown or retail “magic mushrooms.” Psilocybin remains federally controlled; the Drug Enforcement Administration’s psilocybin fact sheet also warns of acute physical and psychological risks from unsupervised use.
Why the issue is moving now
The state framework is receiving fresh attention after federal officials held a public hearing this week on how psychedelic treatments might enter mainstream care while preserving safety standards. In April, the White House directed federal agencies to accelerate research and review of qualifying psychedelic drugs for serious mental illness and to begin relevant scheduling reviews after successful Phase 3 trials.
One closely watched candidate is Compass Pathways’ COMP360, developed for treatment-resistant depression. Axios Richmond reported Wednesday that part of the company’s FDA application is under review and that the company expects to complete its submission by year’s end. A clinical-services company preparing for a possible rollout projects approval by the end of 2026, but that is the company’s estimate, not an FDA timetable.
That distinction prevents the state law from getting ahead of the evidence. FDA approval would require regulators to judge a defined product, indication and administration model, rather than psilocybin use in general. Federal scheduling would then determine the controls placed on that product before Virginia’s board aligns state rules.
What access could look like
If every trigger is met, the treatment described in the law would be administered in a clinical setting under professional supervision rather than dispensed as an ordinary take-home prescription. Axios reported that providers are mapping patient screening, insurance authorization, appointment logistics and several hours of supervised administration. Journey Clinical, which already operates a Charlottesville site for another federally approved depression treatment, said Richmond is part of its expansion planning.
Virginians should therefore treat the law as advance regulatory preparation, not a guarantee of approval, coverage or a launch date. Even after favorable federal action, the Board of Pharmacy’s quarterly schedule could add several months before the state change takes effect. Providers would also need trained staff, compliant sites and payment arrangements.
For now, the practical rule remains unchanged: no psilocybin product is legally available through this Virginia pathway. The next verifiable milestones are completion of a federal application, an FDA decision and any subsequent federal scheduling order.
